...Cellectis and Etablissement Francais du Sang (EFS), the national transfusion service in France, partnered to develop and commercialize red... ...small and medium-sized enterprises (SMEs). Further terms were not disclosed. Cellectis S.A. (Euronext:ALCLS), Romainville, France Etablissement Francais du Sang...
...inactivate blood-borne pathogens in red blood cells intended for transfusion. Cerus Corp. (NASDAQ:CERS), Concord, Calif. Etablissement Francais du Sang...
This Wednesday marks the one-year anniversary of the biotech meltdown prompted by the Clinton-Blair comments about the patentability of genetic information. Coincidentally, the NASDAQ Composite also began its precipitous slide that month, and if it's...
This Wednesday marks the one-year anniversary of the biotech meltdown prompted by the Clinton-Blair comments about the patentability of genetic information. Coincidentally, the NASDAQ Composite also began its precipitous slide that month, and if it's...
MDXN acquired exclusive global rights from the center to the use of fibrin glue-keratinocyte combinations for the treatment of wounds. Etablissement Français du Sang, which owns the Blood Transfusion Center, retains non-exclusive rights in France....
...Cellectis and Etablissement Francais du Sang (EFS), the national transfusion service in France, partnered to develop and commercialize red... ...small and medium-sized enterprises (SMEs). Further terms were not disclosed. Cellectis S.A. (Euronext:ALCLS), Romainville, France Etablissement Francais du Sang...
...inactivate blood-borne pathogens in red blood cells intended for transfusion. Cerus Corp. (NASDAQ:CERS), Concord, Calif. Etablissement Francais du Sang...
This Wednesday marks the one-year anniversary of the biotech meltdown prompted by the Clinton-Blair comments about the patentability of genetic information. Coincidentally, the NASDAQ Composite also began its precipitous slide that month, and if it's...
This Wednesday marks the one-year anniversary of the biotech meltdown prompted by the Clinton-Blair comments about the patentability of genetic information. Coincidentally, the NASDAQ Composite also began its precipitous slide that month, and if it's...
MDXN acquired exclusive global rights from the center to the use of fibrin glue-keratinocyte combinations for the treatment of wounds. Etablissement Français du Sang, which owns the Blood Transfusion Center, retains non-exclusive rights in France....